Xiaoxia Wu

Xiaoxia Wu

Auto-generated profile, based on publicly available information

Xiaoxia Wu

Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University Suzhou China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2020 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
JHJingsheng Hua
Jingsheng Hua
JZJian Zhang
Jian Zhang
XZXinyou Zhang
Xinyou Zhang
XWXiaoxia Wu
Xiaoxia Wu
Lili ZhouLili Zhou
Lili Zhou
HQHuiying Qiu
Huiying Qiu

1 March 2020 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
JHJingsheng Hua
Jingsheng Hua
WQWeiqing Qian
Weiqing Qian
XWXiaoxia Wu
Xiaoxia Wu
LZLili Zhou
Lili Zhou
LYLei Yu
Lei Yu
HQHuiying Qiu
Huiying Qiu
Pediatric Philadelphia chromosome-like (Ph-like) acute B-lymphoblastic leukemia (B-ALL), a high-risk subset of B-ALL characterized by a gene expression profile similar to that of Ph-positive ALL, has extremely poor outcome after a relapse following autologous chimeric antigen receptor (CAR)-T and haploidentical (haplo) hematopoietic stem cell transplantation(HSCT)therapy. with very limited treatment options. Donor-derived CAR T-cell therapy, the most vital advanced anticancer technology, may be a promising salvage strategy for patients with Ph-like B-ALL. Here, we presented a relapsed and refractory case of a child with Ph-like B-ALL after autologous anti-CD19 CAR T-cell therapy followed by haplo-HSCT. She successfully achieved the fourth complete remission (CR4) and maintained CR for five months after the sequential infusion of donor-derived anti-CD22 and anti-CD19 CAR T cells, with mild CRS side effects and no obvious graft-versus-host disease. A donor-derived anti-CD22 and -CD19 CAR T-cell therapy combined with a sequential infusion strategy may provide a promising alternative treatment strategy as effective and safe salvage therapy for children with recurrent and refractory Ph-like B-ALL after autologous CD19-directed CAR T-cell therapy followed by haplo-HSCT.

3 April 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
XWXiaoxia Wu
Xiaoxia Wu
JZJian Zhang
Jian Zhang
QCQiwei Chen
Qiwei Chen
LZLili Zhou
Lili Zhou
MLMengyun Li
Mengyun Li
DWDepei Wu
Depei Wu
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

6 September 2024 in Cancer Medicine
Verified
Journal Article
Open access
XWXiaoxia Wu
Xiaoxia Wu
SLShenqi Lu
Shenqi Lu
XZXinhui Zhang
Xinhui Zhang
ZYZhen Yang
Zhen Yang
ASAining Sun
Aining Sun
MMMiao Miao
Miao Miao
Tyrosine kinase inhibitors (TKIs) have revolutionized Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL) treatment. The combination of blinatumomab and a TKI in the frontline setting has shown the safety and efficacy of the chemotherapy‐free treatment approach in patients with Ph + ALL. This retrospective analysis included 19 patients with Ph + ALL and Ph‐like ALL treated with the combination of blinatumomab and a TKI. Of the 14 newly diagnosed patients, the overall response, complete remission (CR), and molecular response (CMR) rates after one cycle of blinatumomab were 100% (10/10), 90% (9/10), and 57% (8/14), respectively. Of the five relapsed patients, the CR and CMR rates were 50% (2/4) and 40% (2/5). Blinatumomab in combination with TKIs is safe and effective and hence this combination therapy could be a viable therapeutic option in front‐line treatment of patients with Ph + ALL.

1 March 2014 in Transplant Immunology
Verified
Journal Article
Closed access
XWXiaoxia Wu
Xiaoxia Wu
QWQiquan Wan
Qiquan Wan
QYQifa Ye
Qifa Ye
JZJiandang Zhou
Jiandang Zhou

1 January 2020 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
JHJingsheng Hua
Jingsheng Hua
WQWeiqing Qian
Weiqing Qian
XWXiaoxia Wu
Xiaoxia Wu
LZLili Zhou
Lili Zhou
LYLei Yu
Lei Yu
HQHuiying Qiu
Huiying Qiu
Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature [Corrigendum] Hua J, Qian W, Wu X, et al. Onco Targets Ther. 2020;13:2311–2317. The authors of this paper have advised that the author and affiliation list on page 2311 is incorrect. The correct author and affiliation list is as follows:Jingsheng Hua1,2,*Weiqing Qian3,*Xiaoxia Wu1,*Lili Zhou1Lei Yu4Suning Chen1Jian Zhang1Huiying Qiu11Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215006, Jiangsu, People’s Republic of China; 2Department of Hematology, Taizhou Municipal Hospital, Taizhou 318000, Zhejiang, People’s Republic of China; 3Suzhou Vocational Health College, Suzhou, Jiangsu, People’s Republic ofChina; 4College of Chemistry andMolecular Engineering, East China Normal University, Shanghai, People’s Republic of China*These authors contributed equally to this workThe authors have also advised that the correspondence section on page 2311 is incorrect. The correspondence section shouldread as follows:Correspondence: Huiying Qiu; Jian ZhangTel +8613912792913Fax +8651267781850Email qiuhuiying8303@suda.edu.cn; crystalzj06@163.comRead the original article